{"article_title": "Pharmacyclics shares soar after panel says cancer drug met goals", "article_keywords": ["pharmacyclics", "cancer", "developing", "twitter", "shares", "surge", "met", "patients", "imbruvica", "therapy", "goals", "soar", "drug", "panel"], "article_url": "http://blogs.marketwatch.com/health-exchange/2014/01/07/pharmacyclics-shares-soar-after-panel-says-cancer-drug-met-goals/", "article_text": "Pharmacyclics Inc., a company developing cancer treatments, saw its shares soar 18% Tuesday after an independent committee recommended that Phase 3 tests on its Imbruvica drug be stopped because the therapy had already met several goals.\n\nShutterstock\n\nThe drug, used to treat particular forms of leukemia and lymphoma, showed \u201cstatistically significant\u201d improvement in survival rates for patients using Imbruvica versus another drug, Ofatumumab, Pharmacyclics /quotes/zigman/53242/delayed /quotes/nls/pcyc PCYC officials said in a press release.\n\nShares of the company jumped $19.14 to $124.20 in recent action.\n\nPharmacyclics is developing Imbruvica with Johnson & Johnson\u2019s /quotes/zigman/230812/delayed /quotes/nls/jnj JNJ Janssen Pharmaceuticals unit. J&J shares were up 1.7% to $93.88.\n\nThe two companies tested 391 patients at 70 clinics in 10 countries. They now are discussing the next steps with health authorities in the U.S. and Europe.\n\nEpizyme Inc. /quotes/zigman/15507302/delayed /quotes/nls/epzm EPZM also reported Tuesday that it had achieved certain milestones in cancer therapies that it was developing, prompting its shares to surge by 65%.\n\nFollow Russ Britt on Twitter @russbrittmktw\n\nFollow Health Exchange on Twitter @MWHealthBlog\n\nMore health-care news from MarketWatch:\n\nEpizyme shares surge 65% after cancer therapy hits milestone\n\nHealth spending growth stays slow, takes smaller bite from economy\n\nCalculate Obamacare penalty before declining coverage, broker says", "article_metadata": {"article.created": "2014-01-07T12:09:21-05:00", "application-name": "MarketWatch.com", "twitter": {"domain": "Marketwatch.com", "description": "Pharmacyclics shares soar 18% after a committee recommended that it stop Phase 3 tests on a cancer drug because the treatment already had met its goals.", "title": "Pharmacyclics shares soar after panel says cancer drug met goals", "url": "http://blogs.marketwatch.com/health-exchange/2014/01/07/pharmacyclics-shares-soar-after-panel-says-cancer-drug-met-goals/", "image": {"src": "http://s.wsj.net/public/resources/MWimages/MW-BS073_pharma_MG_20140107105149.jpg"}, "site": "MarketWatch", "card": "summary_large_image"}, "article.author": "Russ Britt", "article.section": "Markets", "keywords": "cancer treatment,drug testing,Pharmacyclics Inc.", "article.headline": "Pharmacyclics shares soar after panel says cancer drug met goals", "msapplication-task": "name=SmartMoney;action-uri=http://www.smartmoney.com/;icon-uri=http://www.smartmoney.com/favicon.ico", "news_keywords": "cancer treatment,drug testing,Pharmacyclics Inc.", "author": "Russ Britt", "article.page": "Health Exchange Blog", "description": "Pharmacyclics shares soar 18% after a committee recommended that it stop Phase 3 tests on a cancer drug because the treatment already had met its goals.", "article.published": "2014-01-07T12:09:21-05:00", "ROBOTS": "noarchive, noodp", "msapplication-tooltip": "MarketWatch", "fb": {"url": "http://blogs.marketwatch.com/health-exchange/2014/01/07/pharmacyclics-shares-soar-after-panel-says-cancer-drug-met-goals/", "app_id": 283204329838}, "article": {"publisher": "https://www.facebook.com/marketwatch", "image_count": 2}, "og": {"site_name": "Marketwatch", "description": "Pharmacyclics shares soar 18% after a committee recommended that it stop Phase 3 tests on a cancer drug because the treatment already had met its goals.", "title": "Pharmacyclics shares soar after panel says cancer drug met goals", "url": "http://blogs.marketwatch.com/health-exchange/2014/01/07/pharmacyclics-shares-soar-after-panel-says-cancer-drug-met-goals/", "image": {"width": 569, "identifier": "http://s.wsj.net/public/resources/MWimages/MW-BS073_pharma_MG_20140107105149.jpg", "height": 398}, "type": "article"}, "article.access": "free", "article.type": "Health Exchange", "article.id": "BL-MW243B-1811", "article.updated": "2014-01-07T12:09:21-05:00"}, "_id": "\"57477af36914bd0286fcc4ba\"", "article_summary": "Pharmacyclics Inc., a company developing cancer treatments, saw its shares soar 18% Tuesday after an independent committee recommended that Phase 3 tests on its Imbruvica drug be stopped because the therapy had already met several goals.\nPharmacyclics is developing Imbruvica with Johnson & Johnson\u2019s /quotes/zigman/230812/delayed /quotes/nls/jnj JNJ Janssen Pharmaceuticals unit.\nEpizyme Inc. /quotes/zigman/15507302/delayed /quotes/nls/epzm EPZM also reported Tuesday that it had achieved certain milestones in cancer therapies that it was developing, prompting its shares to surge by 65%.\nFollow Russ Britt on Twitter @russbrittmktwFollow Health Exchange on Twitter @MWHealthBlogMore health-care news from MarketWatch:Epizyme shares surge 65% after cancer therapy hits milestoneHealth spending growth stays slow, takes smaller bite from economyCalculate Obamacare penalty before declining coverage, broker says\nShutterstockThe drug, used to treat particular forms of leukemia and lymphoma, showed \u201cstatistically significant\u201d improvement in survival rates for patients using Imbruvica versus another drug, Ofatumumab, Pharmacyclics /quotes/zigman/53242/delayed /quotes/nls/pcyc PCYC officials said in a press release."}